Sep 28, 2023
As the leaves begin to turn and a crispness fills the air, it's time for businesses and PR professionals to turn over a new leaf as well.
Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001, a First-In-Class NMT Inhibitor, in Non-Hodgkin's Lymphomas and Solid Tumor Patients
September 14, 2021 4:13 PM EDT | Source: Reportable, Inc.
Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage.
- Upcoming enrollment of 20-30 patients to begin at the Cross Cancer Institute in Edmonton and expand to Princess Margaret Hospital in Toronto and the BC Cancer Agency in Vancouver.
- This open label, dose escalation study will examine the safety and tolerability of PCLX-001.
Click image above to view full announcement.
Contacts:
Michael Weickert Ph.D
650-218-1840
michael.weickert@pacylex.com
Source: Pacylex
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96540